AzTrials
AzTrials

Obesity PreventionNCT06619028

External Body Weight Effects on Body Weight in Adults With Grade II and III Obesity

A study testing Weighted vest in people with Obesity Prevention and Obesity, run by Escoles Universitaries Gimbernat at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obesity Prevention, Obesity
What is being tested?
Weighted vest
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteSpain
Study dates
1 Oct 2024to 1 Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age\>18 years
  • BMI (≥35)
  • Compliance at intervention delivery.

Who cannot join

  • Chronic pathology that may hinder the performance of the intervention
  • Chronic pain
  • Regular consumption of pharmacology or supplementation that affects body weight
  • Inability to perform any physical activity or high risk of suffering adverse effects from the interventibariatric-metabolic surgery
  • Reduced mobility
  • Changes of 5kg or more in the last 3 months
Show all 9Show fewer
  • Drastic changes in lifestyle habits in the last 3 months (physical activity, eating habits, nicotine or alcohol consumption)
  • Apparent risk of not being able to complete the study intervention (at the principal investigator\'s discretion)
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Manuel Garcia-San-Emeterio, PhD Student contact

Spain: +34689608040

manuel.garcias@eug.es

Spain1 site
  • EUGimbernat

    Sant Cugat del Vallès, Barcelona, 08174

    Manuel Garcia-San-Emeterio, PhD Student, +34689608040, manuel.garcias@eug.es

Other trials in Spain

About this study

Official title: Effectiveness of the Use of External Body Weight in the Regulation of Body Weight, Body Composition and Analytical Parameters in Adults With Grade II and III Obesity

Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy metabolism.

In this context, the hormone leptin, responsible for regulating appetite and body weight, presents resistance in people with obesity, altering the metabolic balance. Recent research has explored the concept of the "gravitostat", a system that responds to the mechanical stimulus of standing upright, as a promising approach in the regulation of body weight. Animal and human studies have shown positive results in weight loss and body recomposition using this system. However, more research is needed to evaluate the clinical applicability and effectiveness of the gravitostat in the management of obesity.

For this reason, the present study is proposed, with a prospective longitudinal controlled design in the use of external body weight (where the patients are their own control: intrasubject controlled study) during 4 weeks, with a previous control period of 4 weeks and a follow-up of 4 weeks. The proposed objectives are to analyze the effectiveness of the use of external weight in the regulation of body weight, body composition and analytical parameters in people with grade II and III obesity. In this way, to analyze the clinical applicability of the gravitostat in the management of patients with this metabolic pathology.

Read the detailed description

BACKGROUND Obesity is one of the most prevalent and booming health and social problems in recent decades in industrialized societies. Obesity rates in European countries such as the United Kingdom, Germany, France and Spain fluctuate between 23 and 29% in the adult population, according to the World Health Organization (WHO). These values increase to 42.4%, 27% and 31% in the United States, Canada and Australia, respectively, considering data from the last 5 years from the main health agencies of these countries, making it a social and public health problem.

The etiopathogenesis of this condition is multifactorial; the obesogenic characteristics of the environment can influence gene expression conditioning the development of obesity. Increased caloric intake, influenced by high-fat diets (Westerns\' diet), the absence or insufficiency of physical activity and alterations in energy metabolism seem to be the three fundamental factors contributing to the development of obesity. Moreover, these factors seem to play a major role in the development of other metabolic entities such as hypertension, dyslipidemia and insulin resistance or type II diabetes, which, together with central obesity, make up the metabolic syndrome. This clinical entity doubles the risk of coronary and cerebrovascular disease, increases the risk of diabetes fivefold, and increases all-cause mortality by 50%. In parallel to the risk factors listed above, some studies highlight the role of a sedentary lifestyle as a factor independent of physical activity in contributing to the development of metabolic pathology. Not only the absence of low, moderate or high intensity physical activity has been correlated with the development of metabolic syndrome, but also the increase in time spent in sedentary activities, with an odds ratio of 2.38.

These intrinsic and extrinsic factors seem to interact and condition each other, altering homeostatic and physiological processes in obese individuals.

Since its discovery and description in the 1990s by Friedman leptin has been the most important hormonal factor in the regulation and control of caloric intake and metabolism, and consequently of body weight and composition. Its peripheral production at the level of white fat tissue and its hypothalamic effects (decrease in orexic neuronal activity and conditioning of dopaminergic reward circuits) condition the individual\'s response to food, regulating satiety and intake.

Evidence shows that this mechanism is altered in people with obesity where excessive leptin production, due to increased concentrations of fat tissue, and consequently high serum concentrations, condition central and peripheral sensitivity to this hormone, generating, in the long run, lower response efficiency, giving rise to the term "leptin resistance ". This resistance seems to modify the hypothalamic satiety signal, as well as the dopaminergic circuits associated with food intake,predisposing to the appearance or increase of metabolic pathology, especially obesity. This dysregulation in caloric intake appears without alterations in the production and function of ghrelin, a hormone produced in the stomach associated with hunger.

Recent research has proposed a second system of body weight homeostasis associated with the mechanical stimulus of standing upright, coined the term "gravitostat ".

Studies in mice and in humans show promising results in the regulation of body weight and fat percentage by this mechanical system. These investigations have shown significant reductions in both parameters when external weight is added to the study subjects, generating modifications in food intake and caloric expenditure. These adaptations have been tested independently of leptin resistance or the lack of leptin receptors, thus demonstrating the existence of an independent homeostatic regulation pathway. These changes have been shown to be significant only in obese subjects, whereas in normopese subjects, who show greater sensitivity to leptin, the changes produced by the increased load do not appear to be significant. Regarding body recomposition, these studies seem to indicate a maintenance of muscle mass, without experiencing significant losses, as in other contexts of caloric deficit thus prioritizing the loss of white fat tissue (especially visceral) as a mechanism of weight regulation.

Some studies justify this action by the production of fibroblast growth factors (FGF) produced by the osteocytes, specifically, the factor FGF21 associated with the hypothalamic receptor FGFR1c. The triplication in the serum quantities of FGF21 factor, by hepatic expression, in subjects exposed to body weight, seems to justify the increase in fat mobilization and oxidation, as well as the loss of body weight, which, despite the catabolic context, does not affect muscle mass. In any case, the results do not yet seem to be conclusive, since at supraphysiological loads of FGF21 the action of weight loss is mitigated, probably indicating a regulation by the FGFR1c receptor mediated, in part, by one or more other factors. This could be a key factor in the lack of effectiveness in normopese individuals.

Some stuides show how the increased load during the prepubertal period in rats reduces the expression of hormones associated with growth (IGF-1 and GHGH) as a homeostatic mechanism to control sudden weight gain. Similarly, down-regulation of ghrelin receptors at the hypothalamic level is observed, leading to a decrease in caloric intake. Other adaptations that could explain the physiological mechanism of body homeostasis, in this case, during growth.

With respect to analytical parameters, the only clinical trial carried out in humans only shows significant reductions in LDL and leptin; the results are inconclusive for the other parameters studied.

Taking this into consideration, some evidence observed a bidirectional regulation, with increases in body weight and fat mass in subjects with the sudden decrease in load. The lack of follow-up in human studies4 does not allow extrapolation of these results. At the clinical level, this regulation could justify weight and, essentially, fat gain after liposuction interventions6 or other contexts of abrupt weight loss or dietary patterns with aggressive caloric restriction. In this case, both homeostatic systems would influence, on the one hand, the gravitostat would increase food intake and the decrease in adipose tissue and the conditioned reduction in leptin production would decrease anorexic signals, predisposing the subjects to have more frequent and calorically dense intakes.

The results presented by some reserchers are promising in the development of new tools to help patients with obesity, despite this, the short duration of the intervention and the lack of follow-up of the patients, the lack of consistent changes in the analytical analysis, the performance only in young and moderately obese patients, as well as the high demand of the intervention protocol and the sudden gain in body weight after the intervention (in basic studies) make further research necessary to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool, as well as the high demands of the intervention protocol and the sudden gain of body weight after the intervention (in basic studies) make it necessary to carry out further research to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool in patients with obesity.

For this reason, the present doctoral thesis proposes an intrasubject controlled study for a period of 12 weeks (4 control, 4 intervention and 4 follow-up) in patients with grade II and III obesity. During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention, they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle.

For this study, accepting an alpha risk of 0.05 and a beta risk of less than 0.2 in a unilateral contrast, 24 patients are required to detect a difference equal to or greater than 0.15 unit. A common standard deviation of 1.4 and a correlation between the first and second measurement of 0.99 (according to literature) is assumed. A loss rate of 10% is assumed. Patients will be recruited from the endocrinology service of the Hospital Universitario Parc Taulí.

Being tested
Weighted vest
Keywords
Obesity, Body Weight, Weight loss, Treatment, Leptin, Gravitostat
Medical subject headings
Obesity, Body Weight, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Weighted vestDevice

    Also called External load

    During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.

Study groups in NCT06619028
Study groupRoleWhat they receive
Intervention Group (IG)ExperimentalDuring the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
Receives: Device: Weighted vest

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body weight

    Measured fasting weight by electronic scale (BC-545N Tanita)

    Measured: From enrollment to the end of treatment at 12 weeks

Secondary outcomes (11)
  1. Nutritional state

    Short Dietary Questionnaire Punctuation: From 0 to 9. Interpretation: Higher results, better adherence with Mediterranean diet. Lower results, worst adherence with Mediterranean diet.

    Measured: From enrollment to the end of treatment at 12 weeks

  2. Grip Strength

    Measuring tool: Grip Strength Dynamometer Takei T.K.K 5401 Procedure: 3 consecutive measurements with each extremity, taking the mean as reference value for each.

    Measured: From enrollment to the end of treatment at 12 weeks

  3. Lower Extremity Strength

    30' chair stand-up test Test performed only once, with a 43 cm (17 inches) high chair without armrests.

    Measured: From enrollment to the end of treatment at 12 weeks

  4. Activity state

    Minnesota Leisure Time Physical Activity Questionnaire No standared punctuation Higher values associated with higher activity state Punctuation registred in minutes, days, months.

    Measured: From enrollment to the end of treatment at 12 weeks

  5. Absolute frequency of patients reporting adverse effects

    Self-reported ad hoc questionnaire following CTCAE v4.0 criteria

    Measured: From week 4 to the end of treatment at 12 weeks

  6. Body compostiton

    Bioimpedance electrical analysis (BC-545N Tanita) Body fat percentage; no standarized values, lower values are better. Muscle mass percentatge; no standarized values, higher values are better. Bone mass level; no standarized values, higher values are better. Visceral fat level; no standarized values, lower values are better.

    Measured: From enrollment to the end of treatment at 12 weeks

  7. Body compostiton

    Ultrasound measurement of muscle cross-sectional area and fat folds in thigh and abdomen (General Electric VScan) Muscle cross-sectional area: mesured (midpoint from anterosuperior iliac spine and superior pole of patella). 3 mesurements, mean result.

    Fat fold: mesured (midpoint from anterosuperior iliac spine and superior pole of patella). 3 mesurements, mean result.

    Fat fold: mesured (2cm below the umbilicus; subumbilical area). 3 mesurements, mean result.

    Measured: From enrollment to the end of treatment at 12 weeks

  8. Age

    Measured in ages using a self-reported questionnaire.

    Measured: Baseline

  9. Sex

    Measured in dichotomous variable using a self-reported questionnaire.

    Measured: Baseline

  10. Height

    Measurement in centimeters using tape measure

    Measured: Baseline

  11. Body Mass Index

    Calculated by height in meters and weight in kilograms. Following this formula: BMI = weight ÷ height^2 (units: kg/m^2)

    Fallowing this criteria to interpret:

    • lt; 16.0 Severely Underweight 16.0 - 18.4 Underweight 18.5 - 24.9 Normal 25.0 - 29.9 Overweight 30.0 - 34.9 Type I Obesity 35.0 - 39.9 Type II Obesity
    • gt; 40.0 Type III Obesity

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2024
  2. Study start1 Oct 2024 (estimated)
  3. Primary completion1 Jul 2025 (estimated)
  4. Study completion1 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Model description
A prospective longitudinal controlled design on the use of external body weight (where patients are their own control: intrasubject controlled study) for 4 weeks, with a 4-week pre-control period and a 4-week follow-up.
Masking
None (open label)
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06619028
Sponsor's protocol ID
G0001
Status last verified
Sep 2024
First submitted
13 Sep 2024
Last updated
1 Oct 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Palsdottir V, Windahl SH, Hagg DA, Keantar H, Bellman J, Buchanan A, Vaughan TJ, Linden D, Jansson JO, Ohlsson C. Interactions Between the Gravitostat and the Fibroblast Growth Factor System for the Regulation of Body Weight. Endocrinology. 2019 May 1;160(5):1057-1064. doi: 10.1210/en.2018-01002.

    PubMed 30888399
  • Bake T, Peris-Sampedro F, Waczek Z, Ohlsson C, Palsdottir V, Jansson JO, Dickson SL. The gravitostat protects diet-induced obese rats against fat accumulation and weight gain. J Neuroendocrinol. 2021 Aug;33(8):e12997. doi: 10.1111/jne.12997. Epub 2021 Jul 9.

    PubMed 34240761
  • Jansson JO, Dalmau Gasull A, Schele E, Dickson SL, Palsdottir V, Palmquist A, Girones FF, Bellman J, Anesten F, Hagg D, Ohlsson C. A Body Weight Sensor Regulates Prepubertal Growth via the Somatotropic Axis in Male Rats. Endocrinology. 2021 Jun 1;162(6):bqab053. doi: 10.1210/endocr/bqab053.

    PubMed 33693673
  • Jansson JO, Palsdottir V, Hagg DA, Schele E, Dickson SL, Anesten F, Bake T, Montelius M, Bellman J, Johansson ME, Cone RD, Drucker DJ, Wu J, Aleksic B, Tornqvist AE, Sjogren K, Gustafsson JA, Windahl SH, Ohlsson C. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):427-432. doi: 10.1073/pnas.1715687114. Epub 2017 Dec 26.

    PubMed 29279372
  • Ohlsson C, Hagg DA, Hammarhjelm F, Dalmau Gasull A, Bellman J, Windahl SH, Palsdottir V, Jansson JO. The Gravitostat Regulates Fat Mass in Obese Male Mice While Leptin Regulates Fat Mass in Lean Male Mice. Endocrinology. 2018 Jul 1;159(7):2676-2682. doi: 10.1210/en.2018-00307.

    PubMed 29800288
  • Ohlsson C, Gidestrand E, Bellman J, Larsson C, Palsdottir V, Hagg D, Jansson PA, Jansson JO. Increased weight loading reduces body weight and body fat in obese subjects - A proof of concept randomized clinical trial. EClinicalMedicine. 2020 Apr 30;22:100338. doi: 10.1016/j.eclinm.2020.100338. eCollection 2020 May.

    PubMed 32510046
  • Ekblom O, Ekblom-Bak E, Rosengren A, Hallsten M, Bergstrom G, Borjesson M. Cardiorespiratory Fitness, Sedentary Behaviour and Physical Activity Are Independently Associated with the Metabolic Syndrome, Results from the SCAPIS Pilot Study. PLoS One. 2015 Jun 29;10(6):e0131586. doi: 10.1371/journal.pone.0131586. eCollection 2015.

    PubMed 26120842
  • Gallardo-Alfaro L, Bibiloni MDM, Mascaro CM, Montemayor S, Ruiz-Canela M, Salas-Salvado J, Corella D, Fito M, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Fernandez-Garcia JC, Lapetra J, Pinto X, Garcia Rios A, Bueno-Cavanillas A, Gaforio JJ, Matia-Martin P, Daimiel L, Mico-Perez RM, Vidal J, Vazquez C, Ros E, Fernandez-Lazaro CI, Becerra-Tomas N, Gimenez-Alba IM, Zomeno MD, Konieczna J, Compan-Gabucio L, Tojal-Sierra L, Perez-Lopez J, Zulet MA, Casanas-Quintana T, Castro-Barquero S, Gomez-Perez AM, Santos-Lozano JM, Galera A, Basterra-Gortari FJ, Basora J, Saiz C, Perez-Vega KA, Galmes-Panades AM, Tercero-Macia C, Sorto-Sanchez C, Sayon-Orea C, Garcia-Gavilan J, Munoz-Martinez J, Tur JA. Leisure-Time Physical Activity, Sedentary Behaviour and Diet Quality are Associated with Metabolic Syndrome Severity: The PREDIMED-Plus Study. Nutrients. 2020 Apr 7;12(4):1013. doi: 10.3390/nu12041013.

    PubMed 32272653
  • Berthoud HR, Morrison CD, Munzberg H. The obesity epidemic in the face of homeostatic body weight regulation: What went wrong and how can it be fixed? Physiol Behav. 2020 Aug 1;222:112959. doi: 10.1016/j.physbeh.2020.112959. Epub 2020 May 16.

    PubMed 32422162

Questions about this trial

What is this clinical trial studying?

A study testing Weighted vest in people with Obesity Prevention and Obesity, run by Escoles Universitaries Gimbernat at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Manuel Garcia-San-Emeterio, PhD Student (Spain: +34689608040, manuel.garcias@eug.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body weight (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06619028, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in